CTIC CTI BioPharma Corp.

3.27
+0.15  (+5%)
Previous Close 3.12
Open 3.14
52 Week Low 0.62
52 Week High 4.0322
Market Cap $246,791,331
Shares 75,471,355
Float 58,833,981
Enterprise Value $185,095,627
Volume 515,898
Av. Daily Volume 598,181
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Pacritinib
Myelofibrosis
NDA Filing
NDA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Pacritinib
COVID-19
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Pacritinib
Graft Vs Host Disease
Phase 1/2
Phase 1/2
Phase 1/2 data presented at ASH December 6, 2020.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3
Phase 3
Phase 3 data released July 9. 2018. Primary endpoint not met.
OPAXIO
Ovarian cancer
Phase 3
Phase 3
Phase 3 - noted July 2016 that unlikely to have survival benefit

Latest News

  1. SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: The JMP Securities Hematology Summit
    Date: Tuesday, Dec. 15
    Time: 3:00 p.m. EST

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.
    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We…

    SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: The JMP Securities Hematology Summit

    Date: Tuesday, Dec. 15

    Time: 3:00 p.m. EST

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-summit-on-tuesday-dec-15-301187816.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  2. SEATTLE, Dec. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of acute graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5-8, 2020. The results are from an investigator-sponsored Phase 1/2 study conducted at the Mayo Clinic and Moffit Cancer Center.

    "The data presented today at ASH highlights the potential for the expanded use of pacritinib. Acute GVHD following allogeneic hematopoietic cell transplantation results in higher rates of morbidity and mortality, compromises the anti-leukemic response of the graft and occurs despite standard immunosuppressive prophylaxis, rendering it an area where new therapeutic options are needed," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "These data demonstrate that in this Phase 1/2 study, adding pacritinib to the standard prophylaxis of sirolimus and low-dose tacrolimus resulted in a significant reduction in the expected acute GVHD rates in patients within the first 100 days of therapy as compared to historical data, without compromising transplantation outcomes and without any new safety concerns. We are encouraged by these data, and look forward to further evaluating pacritinib's efficacy and safety in this indication in the on-going Phase 2 clinical trial."

    All presentation materials will be available at ctibiopharma.com following the presentations.

    Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase 1 / 2 Study Results

    Results from an investigator-sponsored (Mayo Clinic and Moffit Cancer Center) Phase 1/2 study of GVHD prophylaxis for allogeneic hematopoietic cell transplantation (alloHCT) using pacritinib, sirolimus, low-dose tacrolimus are being presented today, Sunday, December 6 at 10 a.m. PT in an oral presentation session.

    Abstract: No. 355

    Summary: This single-arm Phase 1/2 study (NCT02891603) tested the safety, pharmacodynamics and efficacy of pacritinib when administered with sirolimus plus low-dose tacrolimus (PAC/SIR/TAC) after alloHCT. A 3+3 dose escalation design was planned using three doses of pacritinib (100 mg QD, 100 mg BID, 200 mg BID) in combination with standard sirolimus and low-dose tacrolimus immunosuppressive therapy. Efficacy endpoints included acute GVHD (aGVHD) rate at day 100.

    PAC 100 mg twice daily (BID), dose level 2, was selected as the recommended Phase 2 dose based on its biological activity and safety profile. Preliminary evidence of the benefit of adding pacritinib to standard immunosuppressive therapy in reducing the rates of aGVHD was reported, with a 25% rate of grade 2-4 aGVHD across all dose cohorts, and 17% at the recommended Phase 2 dose of 100 mg BID, as compared to grade 2-4 aGVHD incidence rate of 43% expected with sirolimus plus low-dose tacrolimus administered alone1. No compromise in alloHCT outcome or major safety concerns were observed.  Futher, there was no evidence of cytopenias, impaired immune reconstitution, or cytomegalovirus (CMV) reactivation. A Phase 2 clinical trial to fully evaluate efficacy in GVHD prevention is ongoing (NCT02891603).

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in the prevention of acute graft versus host disease and in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of pacritinib in various indications; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; our planned commercialization of pacritinib; our ability to enter into potential partnerships relating to our commercial launch of pacritinib; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    1. Pidala et al, Oral Presentation, Abstract 355, ASH 2020.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-presentation-of-data-supporting-pacritinibs-potential-benefit-in-preventing-acute-gvhd-at-the-62nd-american-society-of-hematology-meeting-301186889.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  3. SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Determining the Recommended Dose of Pacritinib: Results from the PAC203 Phase 2 Dose-Finding Study in Patients with Advanced Myelofibrosis" is available online via this link.

    "Having recently announced the start of a rolling NDA submission for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, a patient population with reduced survival and limited therapeutic options, we continue to be committed to adding to the growing body of evidence underscoring the efficacy and safety profile of pacritinib," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "As our application will consist of a data package from the PERSIST-1, PERSIST-2 and PAC203 Phase 2 trials, with the ongoing Phase 3 PACIFICA trial expected to be completed as a post-marketing commitment, the data published today support our belief that pacritinib has the potential to become an important treatment in this disease setting, pending regulatory approval."

    PAC203 Phase 2 was an open-label, randomized, dose-finding trial of pacritinib in patients with myelofibrosis who were previously treated with ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg daily (QD), 100 mg BID, or 200 mg BID. The trial demonstrated that pacritinib 200 mg BID had a favorable benefit risk profile. Spleen volume response (SVR) rates were highest among patients treated with pacritinib 200 mg BID who had a baseline platelet count of less than 50 x 109/L. Overall, the study data supported the selection of the pacritinib 200 mg BID for use in the ongoing Phase 3 PACIFICA study of pacritinib in patients with myelofibrosis with severe thrombocytopenia.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of pacritinib; our ability to complete a rolling NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; our planned commercialization of pacritinib; our ability to enter into potential partnerships relating to our commercial launch of pacritinib; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-publication-of-article-highlighting-pacritinib-data-from-the-pac203-phase-2-study-in-myelofibrosis-in-blood-advances-301181337.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  4. SEATTLE, Nov. 10, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020.

    "This past quarter we made significant progress in our pacritinib development program. We recently announced the initiation of our rolling New Drug Application (NDA) submission for pacritinib in myelofibrosis patients with severe thrombocytopenia, following a productive Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) on how pacritinib could address the unmet need of this population, which includes both front-line treatment-naïve patients and patients with prior exposure to JAK2 inhibitors," said Adam R. Craig, M.D., Ph.D. "The NDA submission package will…

    SEATTLE, Nov. 10, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020.

    "This past quarter we made significant progress in our pacritinib development program. We recently announced the initiation of our rolling New Drug Application (NDA) submission for pacritinib in myelofibrosis patients with severe thrombocytopenia, following a productive Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) on how pacritinib could address the unmet need of this population, which includes both front-line treatment-naïve patients and patients with prior exposure to JAK2 inhibitors," said Adam R. Craig, M.D., Ph.D. "The NDA submission package will be based on available data from the completed Phase 3 PERSIST-1 and PERSIST-2, and the Phase 2 PAC203 trials, and we expect to complete the submission in the first quarter of 2021. Additionally, we have started pre-commercial activities in preparation for a commercial launch in 2021, subject to priority review."

    Expected Milestones

    • Oral presentation of preclinical and Phase 1 trial data of pacritinib in acute graft-versus-host disease (GVHD) at American Society of Hematology (ASH) 2020 – December 6, 2020
    • Expected completion of rolling NDA submission for pacritinib in myelofibrosis patients with severe thrombocytopenia – Q1 2021
    • Reporting of interim analysis from the Phase 3 PRE-VENT trial in hospitalized patients with severe COVID-19 –First half of 2021

    Third Quarter Financial Results

    Operating loss was $11.0 million and $33.0 million for the three and nine months ended September 30, 2020, respectively, compared to an operating loss of $9.7 million and $31.2 million for the respective periods in 2019. Operating loss for the three months ended September 30, 2020 as compared to the comparable period in 2019 resulted primarily from a decrease in license and contract revenues. The increase in operating loss for the nine months ended September 30, 2020 as compared to the comparable period in 2019 resulted primarily from the recording of a full allowance against certain VAT receivables due to a reduced certainty of collectability.

    No revenues were recognized for the three and nine months ended September 30, 2020, while revenues of $2.3 million and $3.3 million, respectively, were recognized for the comparable periods in 2019. License and contract revenues in 2019 resulted from royalty and other revenues recognized from Les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") and related to the asset purchase agreement and transition period activities pursuant to the terms of the Termination and Transfer Agreement with Servier.

    Net loss for the three months ended September 30, 2020 was $11.3 million, or $0.15 for basic and diluted loss per share, compared to net loss of $10.0 million, or $0.17 for basic and diluted loss per share, for the same period in 2019. Net loss for the nine months ended September 30, 2020 was $37.4 million, or $0.54 for basic and diluted loss per share, compared to net loss of $31.8 million, or $0.55 for basic and diluted loss per share, for the same period in 2019.

    As of September 30, 2020, cash, cash equivalents and short-term investments totaled $57.4 million, compared to $33.7 million as of December 31, 2019. We expect current cash, cash equivalents and short-term investments will enable us to fund our operations into the fourth quarter of 2021.

    Conference Call and Webcast

    CTI will host a conference call and webcast to review its third quarter 2020 financial results and provide an update on business activities today, November 10 at 4:30 PM ET. To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 5504037. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our ability to submit a rolling NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    (tables follow)

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)





    Three Months Ended

     September 30,



    Nine Months Ended

     September 30,



    2020



    2019



    2020



    2019

    License and contract revenues

    $





    $

    2,289





    $





    $

    3,345



    Operating costs and expenses:















    Research and development

    6,994





    7,598





    16,457





    19,126



    General and administrative

    4,052





    4,403





    12,316





    14,662



    Restructuring expenses













    794



    Other operating expenses









    4,200







    Total operating costs and expenses

    11,046





    12,001





    32,973





    34,582



    Loss from operations

    (11,046)





    (9,712)





    (32,973)





    (31,237)



    Non-operating income (expense):















    Interest income

    25





    276





    187





    1,003



    Interest expense

    (115)





    (240)





    (419)





    (803)



    Amortization of debt discount and issuance costs

    (131)





    (131)





    (391)





    (391)



    Foreign exchange gain (loss)

    4





    (240)





    (79)





    (409)



    Loss on dissolution of majority-owned subsidiary









    (3,774)







    Total non-operating expense, net

    (217)





    (335)





    (4,476)





    (600)



    Net loss before noncontrolling interest

    (11,263)





    (10,047)





    (37,449)





    (31,837)



    Noncontrolling interest













    5



    Net loss

    $

    (11,263)





    $

    (10,047)





    $

    (37,449)





    $

    (31,832)



    Basic and diluted net loss per common share

    $

    (0.15)





    $

    (0.17)





    $

    (0.54)





    $

    (0.55)



    Shares used in calculation of basic and diluted net loss per common share:

    73,712





    57,974





    69,966





    57,973



     

    Balance Sheet Data (unaudited):



    (amounts in thousands)





    September 30,



    December 31,





    2020



    2019

    Cash and cash equivalents



    $

    45,301





    $

    31,144



    Short-term investments



    12,111





    2,522



    Working capital



    44,169





    17,092



    Total assets



    63,091





    46,280



    Current portion of long-term debt



    5,658





    4,812



    Long-term debt, less current portion







    4,455



    Total stockholders' equity



    46,819





    17,930



     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-third-quarter-2020-financial-results-301170192.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  5. SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020.

    The details of the presentation are as follows:

    Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results
    Session Name: Clinical Allogeneic Transplantation; Acute and Chronic GVHD, Immune Reconstitution Phase I and II Trials
    Session Number: 722
    Session Date: Sunday, December 6, 2020
    Session Time: 9:30 a.m. - 11:00 a.m. PT
    Presentation Time: 10:00 a.m. PT
    Presenter:

    SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020.

    The details of the presentation are as follows:

    Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results

    Session Name: Clinical Allogeneic Transplantation; Acute and Chronic GVHD, Immune Reconstitution Phase I and II Trials

    Session Number: 722

    Session Date: Sunday, December 6, 2020

    Session Time: 9:30 a.m. - 11:00 a.m. PT

    Presentation Time: 10:00 a.m. PT

    Presenter: Dr. Joseph Pidala

    A copy of the abstract is available here.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-oral-presentation-at-the-62nd-american-society-of-hematology-meeting-301166463.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
View All CTI BioPharma Corp. News